Skip to main content
placeholder image

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.

Journal Article


Abstract


  • Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.

Publication Date


  • 2005

Citation


  • Valle, J. W., Dangoor, A., Beech, J., Sherlock, D. J., Lee, S. M., Scarffe, J. H., . . . Ranson, M. (2005). Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.. British journal of cancer, 92(4), 628-630. doi:10.1038/sj.bjc.6602394

Web Of Science Accession Number


Start Page


  • 628

End Page


  • 630

Volume


  • 92

Issue


  • 4

Abstract


  • Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.

Publication Date


  • 2005

Citation


  • Valle, J. W., Dangoor, A., Beech, J., Sherlock, D. J., Lee, S. M., Scarffe, J. H., . . . Ranson, M. (2005). Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.. British journal of cancer, 92(4), 628-630. doi:10.1038/sj.bjc.6602394

Web Of Science Accession Number


Start Page


  • 628

End Page


  • 630

Volume


  • 92

Issue


  • 4